|Bristol-Myers Says Orencia Approved by EU; Anacor Announces GSK Has Discontinued GSK2251052|
|By Staff and Wire Reports|
|Friday, 05 October 2012 18:24|
Bristol-Myers Squibb (NYSE:BMY) announced the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).
Anacor Pharmaceuticals (NASDAQ: ANAC) announced its collaboration partner GlaxoSmithKline (GSK) has discontinued clinical development of GSK2251052. As previously disclosed, GSK halted the most recent clinical trials of GSK2251052 due to the identification of microbiological findings of resistance in a small number of patients in the Phase 2b trial for the treatment of complicated urinary tract infections (cUTI).
Since then, GSK has conducted additional pre-clinical research and, after assessing various options, has elected to discontinue further development of GSK2251052 and return all rights to GSK2251052 to Anacor. Anacor and GSK are currently working together to transition GSK2251052 back to Anacor.
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its collaboration partner GlaxoSmithKline (GSK) has discontinued clinical development of GSK2251052.
Biodel Inc. (Nasdaq: BIOD) today announced it will be hosting a meeting for analysts and investors on October 11, 2012 in New York.
BIO-key International, Inc. (OTCBB: BKYI), a global leader in fingerprint biometric identification solutions and advanced mobile identification technology, today reported that the company will be presenting at the American Association of Blood Banks - Annual Meeting and CTTXPO, at the Boston Convention Center, October 6th - 9th, 2012 (Booth # 1221).
BioNeutral Group, Inc., (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced the addition of three new members to its board of directors.
Cytori Therapeutics (NASDAQ:CYTX) announced that three oral presentations related to its cell therapy are being presented today at the 10th annual International Federation for Adipose Therapeutics and Sciences meeting.
Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Tuesday, October 30, 2012, at 9:00 a.m. ET to review third quarter financial results.
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has obtained a committed issuer managed equity financing facility under which it may from time to time sell up to $45 million of its registered common stock to Terrapin Opportunity, L.P., over a 24-month period.
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced that Robert T. McNally, Ph.D., President and CEO, will present at the 11th Annual BIO Investor Forum on Wednesday, October 10, 2012, at the Palace Hotel in San Francisco, CA.
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has been named Best Mid-Stage Product Development Company by the Philadelphia Business Journal as part of the Journal's Life Sciences Awards, an annual program recognizing the region's "medical miracle makers for their innovative approaches to improving the delivery of health care."
MannKind Corporation (Nasdaq: MNKD) today announced that it has completed recruiting patients for two Phase 3 clinical studies of AFREZZA® (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind’s to-be-marketed next-generation inhaler.
PerkinElmer, Inc., (NYSE:PKI) a global leader focused on improving the health and safety of people and the environment, today announced that on Thursday, October 25, 2012, after market close, the Company will release third quarter 2012 results.
PharMerica Corporation (NYSE:PMC) announced today that it will provide an online simulcast of its third quarter 2012 earnings conference call on Friday, November 2, 2012.
UMED Holdings, Inc. (PINKSHEETS: UMED), a Texas Corporation, through its acquisition of Mamaki of Hawaii, Inc., owner and operator of Wood Valley Plantation, operates the largest producer of Mamaki herbal tea in the world.